Meta tags:
keywords=;
description=;

Headings (most frequently used words):

you, about, to, exit, abbott, website, investors, newsroom, responsibility, careers, press, releases, are, for, another, country, or, region, specific, do, wish, continue, and, this, subscribe, consumers, healthcare, professionals, partners, contact, site, map, policies, privacy, policy, terms, conditions,

Text of the page (most frequently used words):
and (27), the (25), #abbott (25), cancer (19), 2026 (13), from (10), early (9), for (8), with (8), detection (8), breast (8), loading (7), may (7), diagnostics (7), are (6), our (6), session (6), test (6), june (6), treatment (6), risk (6), overview (6), site (5), about (5), data (5), healthcare (5), more (5), screening (5), monday (5), recurrence (5), prospective (5), study (5), professionals (5), you (4), website (4), that (4), its (4), privacy (4), people (4), portfolio (4), neoadjuvant (4), disease (4), mced (4), patient (4), asco (4), care (4), press (4), responsibility (4), careers (4), faqs (4), this (3), products (3), all (3), without (3), policy (3), time (3), chemotherapy (3), her2 (3), trial (3), times (3), tumor (3), informed (3), evaluation (3), mrd (3), multi (3), how (3), decisions (3), evidence (3), across (3), share (3), content (3), releases (3), contact (3), consumers (3), subscribe (3), events (3), exit (2), please (2), have (2), requested (2), country (2), region (2), information (2), medical (2), devices (2), other (2), not (2), countries (2), specific (2), product (2), use (2), trade (2), further (2), preferences (2), terms (2), conditions (2), policies (2), life (2), facebook (2), linkedin (2), colonoscopy (2), based (2), tests (2), analysis (2), role (2), versus (2), high (2), systemic (2), score (2), validation (2), patients (2), molecular (2), residual (2), testing (2), whole (2), triple (2), negative (2), partner (2), psychological (2), impact (2), reported (2), outcomes (2), through (2), clinical (2), presentations (2), monitoring (2), remission (2), oncology (2), precise (2), improved (2), burden (2), new (2), demonstrate (2), earlier (2), showcases (2), expanding (2), newsroom (2), investors (2), glance (2), heritage (2), who (2), search (2), jobs (2), conferences (2), benefits (2), culture (2), students (2), working (2), news (2), yes, wish, continue, aware, intended, residents, particular, noted, result, contain, pharmaceuticals, uses, those, approved, regions, also, optimized, your, screen, size, another, unless, otherwise, specified, service, names, appearing, internet, trademarks, owned, licensed, subsidiaries, affiliates, any, trademark, name, dress, made, prior, written, authorization, except, identify, services, company, rights, reserved, read, legal, notice, details, submit, eventtype, pageurl, advertising, myabbott, consumer, health, media, laura, anderson, 608, 910, 0914, financial, michael, comilla, 224, 668, 1872, source, global, leader, helps, live, fully, stages, changing, technologies, spans, spectrum, leading, businesses, nutritionals, branded, generic, medicines, 122, 000, colleagues, serve, than, 160, connect, youtube, instagram, com, adenoma, following, stool, colorectal, follow, systematic, network, meta, online, only, cologuard, development, endometrial, vaginal, swab, pipeline, innovation, adjuvant, dose, density, schedule, biologically, pooled, wsg, adapt, planb, trials, cytokine, dynamics, during, endocrine, therapy, cdk4, inhibition, luminal, results, geicam, 2019, carabela, gene, redirects, surgical, pathways, multicenter, driven, stratification, distant, node, positive, independent, nsabp, oncotype, characteristics, undergoing, assay, exome, genome, sequencing, circulating, dna, assays, tnbc, receiving, nac, olaparib, sub, oncodetect, multicancer, blood, smartphone, recognition, assessment, non, invasive, crane, biomarker, class, japan, beyond, five, year, behaviors, perceptions, detect, participants, cancerguard, abstract, inflection, point, playing, increasingly, central, detected, treated, managed, said, jake, orville, senior, vice, president, business, combining, tools, used, guidance, helping, clinicians, make, every, stage, indicate, shift, toward, personalized, clearer, adding, stress, nyse, abt, will, present, abstracts, featuring, continuum, american, society, annual, meeting, taking, place, chicago, showcase, breadth, integrated, support, critical, decision, points, identifying, detecting, guiding, prnewswire, park, ill, show, low, anxiety, minimal, real, world, enhanced, sensitivity, highlight, enable, close, download, res, photos, twitter, back, map, partners, fund, sustainability, social, executive, team, experts, honors, contacts, governance, resources, stock, info, financials,

Text of the page (random words):
abbott showcases expanding evidence across its cancer diagnostics portfolio at asco 2026 may 26 2026 investors overview financials stock info resources news events governance newsroom news press releases press contacts honors experts executive team responsibility overview social impact sustainability abbott fund subscribe consumers consumers healthcare professionals healthcare professionals careers overview working with us professionals students our people and culture benefits faqs conferences events search jobs careers overview working with us professionals students our people and culture benefits faqs conferences events search jobs about abbott overview who we are our heritage abbott at a glance abbott faqs contact us responsibility subscribe about abbott overview who we are our heritage abbott at a glance abbott faqs contact us responsibility subscribe consumers healthcare professionals careers about abbott careers investors newsroom responsibility partners contact site map policies privacy policy terms conditions press releases back to press releases abbott showcases expanding evidence across its cancer diagnostics portfolio at asco 2026 share content to facebook share content to linkedin share content to twitter photos 1 may 26 2026 download hi res close data highlight how screening and diagnostics enable earlier detection more precise treatment decisions and improved patient outcomes from risk to remission new mrd data from the partner study demonstrate enhanced sensitivity in early triple negative breast cancer early mced prospective data show low anxiety and minimal psychological burden in real world use abbott park ill may 26 2026 prnewswire abbott nyse abt will present 11 abstracts featuring new evidence across the cancer care continuum at the american society of clinical oncology asco annual meeting taking place may 29 june 2 2026 in chicago the presentations showcase the breadth of abbott s integrated cancer diagnostics portfolio and demonstrate how its tests support critical decision points from identifying risk and detecting disease earlier to guiding treatment and monitoring for recurrence the data indicate a shift in oncology toward more precise detection improved personalized care and clearer treatment decisions without adding patient burden or stress cancer care is at an inflection point and diagnostics are playing an increasingly central role in how the disease is detected treated and managed said jake orville senior vice president abbott s cancer diagnostics business by combining tools used for screening early detection treatment guidance and recurrence monitoring we re helping clinicians make more informed decisions at every stage of cancer care from risk through remission abstract presentations at asco 2026 the cancerguard multi cancer early detection mced test session times monday june 1 2026 from 1 30 p m to 4 30 p m ct beyond detection five year screening behaviors and patient reported perceptions in detect a participants cancer recognition and assessment through non invasive evaluation crane a prospective clinical validation study of a multi biomarker class multi cancer early detection mced test in japan prospective evaluation of the psychological impact of multicancer early detection mced blood testing a smartphone based patient reported outcomes study the oncodetect molecular residual disease mrd test session times monday june 1 2026 from 1 30 p m to 4 30 p m ct evaluation of whole exome whole genome sequencing tumor informed circulating tumor dna mrd assays in patients with early triple negative breast cancer tnbc receiving neoadjuvant chemotherapy nac with or without olaparib a prospective sub study of the partner trial characteristics of cancer patients undergoing molecular residual disease testing with a tumor informed assay the oncotype dx breast recurrence score test session times monday june 1 2026 from 1 30 p m to 4 30 p m ct ai driven risk stratification for distant recurrence in node positive er her2 early breast cancer independent validation in the nsabp b 28 trial neoadjuvant 21 gene breast recurrence score redirects surgical and systemic treatment pathways in early breast cancer a multicenter prospective study systemic cytokine dynamics during neoadjuvant chemotherapy versus endocrine therapy and cdk4 6 inhibition in high risk luminal breast cancer results from the geicam 2019 01 carabela trial session time monday june 1 2026 at 10 51 a m role of neoadjuvant versus adjuvant chemotherapy dose density and treatment schedule in biologically high risk hr her2 breast cancer a pooled analysis of the wsg adapt hr her2 and planb trials pipeline innovation session time monday june 1 2026 from 9 00 a m to 12 00 p m ct development of an endometrial cancer test from a vaginal swab the cologuard test session time online only adenoma detection following screening colonoscopy and stool based colorectal cancer screening tests with follow up colonoscopy a systematic and network meta analysis about abbott abbott is a global healthcare leader that helps people live more fully at all stages of life our portfolio of life changing technologies spans the spectrum of healthcare with leading businesses and products in diagnostics medical devices nutritionals and branded generic medicines our 122 000 colleagues serve people in more than 160 countries connect with us at abbott com and on linkedin facebook instagram x and youtube source abbott for further information abbott media laura anderson 608 910 0914 or abbott financial michael comilla 224 668 1872 policies terms conditions privacy policy consumer health data privacy policy myabbott privacy preferences advertising preferences pageurl eventtype submit 2026 abbott all rights reserved please read the legal notice for further details unless otherwise specified all product and service names appearing in this internet site are trademarks owned by or licensed to abbott its subsidiaries or affiliates no use of any abbott trademark trade name or trade dress in this site may be made without the prior written authorization of abbott except to identify the product or services of the company you are about to exit for another abbott country or region specific website please be aware that the website you have requested is intended for the residents of a particular country or region as noted on that site as a result the site may contain information on pharmaceuticals medical devices and other products or uses of those products that are not approved in other countries or regions the website you have requested also may not be optimized for your specific screen size do you wish to continue and exit this website yes no loading loading loading loading loading loading loading